Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade B 21.75 -1.81% -0.40
SGMO closed down 1.81 percent on Friday, March 23, 2018, on 73 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical SGMO trend table...

Date Alert Name Type % Chg
Mar 23 Fell Below 50 DMA Bearish 0.00%
Mar 23 Wide Bands Range Expansion 0.00%
Mar 23 Below Lower BB Weakness 0.00%
Mar 23 Down 3 Days in a Row Weakness 0.00%
Mar 23 Lower Bollinger Band Touch Weakness 0.00%
Mar 23 Oversold Stochastic Weakness 0.00%
Mar 22 Stochastic Reached Oversold Weakness -1.81%
Mar 22 Strong but Oversold Other -1.81%
Mar 22 Wide Bands Range Expansion -1.81%
Mar 22 Below Lower BB Weakness -1.81%

Older signals for SGMO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Is SGMO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.5
52 Week Low 4.05
Average Volume 2,138,477
200-Day Moving Average 14.9915
50-Day Moving Average 22.08
20-Day Moving Average 24.3625
10-Day Moving Average 23.985
Average True Range 1.5111
ADX 22.34
+DI 17.43
-DI 23.52
Chandelier Exit (Long, 3 ATRs ) 22.9667
Chandelier Exit (Short, 3 ATRs ) 26.2333
Upper Bollinger Band 26.9106
Lower Bollinger Band 21.8144
Percent B (%b) -0.01
BandWidth 20.918214
MACD Line 0.1592
MACD Signal Line 0.7238
MACD Histogram -0.5646
Fundamentals Value
Market Cap 1.82 Billion
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -26.85
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.00
Resistance 3 (R3) 24.23 23.72 23.63
Resistance 2 (R2) 23.72 23.14 23.60 23.50
Resistance 1 (R1) 22.73 22.79 22.48 22.50 23.37
Pivot Point 22.22 22.22 22.09 22.10 22.22
Support 1 (S1) 21.23 21.64 20.98 21.00 20.13
Support 2 (S2) 20.72 21.29 20.60 20.00
Support 3 (S3) 19.73 20.72 19.88
Support 4 (S4) 19.50